MedTrace Logo

Neuroimaging Study of Dexmedetomidine-Induced Analgesia

NCT04656470 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2026-04-23

Study results available
· View outcomes & findings →

Summary

Neuroimaging data will be collected for patients that are given low doses of dexmedetomidine in order to understand its analgesic effects.

Conditions

  • Analgesia
  • Anesthesia

Interventions

DRUG

Dexmedetomidine

Patients will be delivered dexmedetomidine anesthesia to gain greater understanding of its analgesic effects.

Sponsors & Collaborators

Principal Investigators

  • Oluwaseun Johnson-Akeju, MD, MMSc · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-04
Primary Completion
2025-05-27
Completion
2025-05-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04656470 on ClinicalTrials.gov